Mumbai: Global pharma major Lupin Limited has announced the launch of an authorized generic version of Ravicti (Glycerol ...

Key Highlights Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up ...

Pittsburgh: Viatris Inc., a global healthcare company, has announced it has acquired Aculys Pharma, Inc., a clinical-stage ...

A New York Times health reporter explains what makes a good study, and how she knows which papers merit an article.

A large study shows risperidone raises stroke risk in patients with dementia, even those without cardiovascular disease — ...

Choosing the right career path after completing 12th grade in the science stream is crucial for securing a lucrative and ...

Initiative will establish the world’s largest African ancestry research dataset and close critical gaps in genomic and ...

The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients[i] New findings from this investigational study build on the strength of the data for amivantamab in ...

Two clinical trials of Merck’s pulmonary arterial hypertension (PAH) drug Winrevair were so conclusive that the studies were halted within the last year because the efficacy of the treatment was ...

Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod ...